To determine whether combination therapy affects the effector function of tumor-infiltrating lymphocytes (TILs), we examined the effector and activation molecules GzmB, IFN-γ, and CD69 on CD8+, Foxp3-CD4+, Foxp3+CD4+ T cells and NK cells in the TME at 96 h after treatment by using multi-color flow cytometry (Figures 3A,I). The gene discussed is FOXP3; the disease is neoplasm.